Home / Science / AI Breakthrough Unlocks Faster Antibody Design for Drugs
AI Breakthrough Unlocks Faster Antibody Design for Drugs
10 Nov
Summary
- Nobel Prize-winning scientist leads team using AI to create new antibodies
- AI model can design antibodies in weeks, without animal testing
- Antibodies designed to target cancer proteins, a challenging task

In a remarkable development, a team of researchers led by Nobel Prize-winning scientist David Baker has leveraged artificial intelligence to create entirely new functional antibodies. This breakthrough, published in Nature on November 9, 2025, could significantly accelerate the drug development process using cutting-edge technology.
The researchers at the University of Washington have demonstrated how a generative AI model, dubbed RFantibody, can be used to design novel antibodies—proteins produced by the immune system to block infections—from scratch. Traditionally, the process of discovering and developing antibodies for pharmaceutical use has been expensive, time-consuming, and reliant on extensive animal testing. However, the AI-powered approach pioneered by Baker's team has the potential to shorten this process to just a matter of weeks, without the need for animal immunization.


